Welcome to our dedicated page for Nymox Pharm news (Ticker: NYMXF), a resource for investors and traders seeking the latest updates and insights on Nymox Pharm stock.
Nymox Pharmaceutical Corporation develops prostate-disease treatments centered on NYMOZARFEX, also described as fexapotide, for benign prostatic hyperplasia and low-grade localized prostate cancer. Company updates commonly address clinical follow-up data, marketing-authorization work, regulatory correspondence, and the product's use as an in-office procedure without anesthesia or analgesia.
Nymox news also covers public-company status and governance matters, including OTCQB trading under NYMXF, annual-report timing, board changes, executive share purchases, and litigation developments involving former personnel or shareholder-related claims. These releases frame the company as a foreign pharmaceutical issuer focused on prostate-treatment commercialization and related corporate controls.
Nymox (OTCQB: NYMXF) announced a formal agreement with the Global Alliance of Regenerative Medicine (GARM)/b) on Roatan Island to offer its prostate drug to men seeking treatment and improved prostate health.
Nymozarfex will be provided by certified urologists at GARM’s fully licensed, state-of-the-art facility for international medical tourists.
Nymox Pharmaceutical (OTCQB:NYMXF) reported an update on Nymozarfex. The company is focusing on re-submitting for US marketing approval after the initial US filing was not accepted for review. Prior Denmark and UK submissions were fully reviewed but refused and would need updated re-submissions.
According to Nymox, reviewers questioned placebo effects and practical benefits of long-term efficacy, despite Phase 3 long-term double-blind data showing a p value of 0.0003 vs placebo. Management says additional financing is required to pursue further regulatory re-submissions.
Nymox Pharmaceutical (OTCQB:NYMXF) announced Board changes and corporate updates on March 27, 2026. Patrick Doody has retired from the Board and the company confirmed the recent passing of Co-Chairman James G. Robinson. The company said prostate treatment dossiers were significantly updated but no major approvals yet.
CEO Paul Averback MD purchased 50,000 shares in the open market, adding to a prior October 2025 purchase of 102,844 shares.
Nymox has announced the dismissal of its Delaware legal action against Ascella on March 7, 2025. The company stated this decision came after reconsidering its strategy to protect shareholders' interests. CEO Paul Averback indicated this dismissal is a legal step taken after consultation with legal counsel, and mentioned that additional steps are being contemplated, which will be reported at an appropriate time.
Nymox Pharmaceutical (NYMXF) has announced the resumption of its stock trading on the OTCQB Venture Market, representing an upgrade from its previous listing tier. This new listing makes the stock eligible for proprietary broker-dealer quotations. The company's president, Paul Averback, expressed gratitude towards the OTC teams for their guidance during the transition process and thanked shareholders and investors for their patience and support. He emphasized the company's focus on advancing prostate treatments to address the market's need for safer and more effective solutions.
Nymox Pharmaceutical (OTC: NYMXF) has announced the filing of its Annual Report with the Securities and Exchange Commission (SEC) on August 29, 2024. The company, which trades on the OTC Markets, made this announcement on August 30, 2024, from Irvine, California. This timely filing of the Annual Report is a important regulatory compliance step for publicly traded companies, providing investors and regulators with essential financial and operational information about the company's performance over the past year.
Nymox Pharmaceutical (OTC: NYMXF) has announced an update on its Annual Report progress. The company began working on the report in late February after receiving previously withheld corporate documents from terminated officers and directors. This situation has led to unexpected delays in completing the report. Despite these challenges, Nymox expects the audit to be finalized soon, with the Annual Report to be issued shortly after. The company acknowledges the delay is beyond its control and is working to release the report as quickly as possible.
Nymox Pharmaceutical (OTC: NYMXF) announced that its Marketing Authorization Application (MAA) to the Danish Medicines Agency (DKMA) for Nymozarfex™ has expired and requires resubmission with a new fee. The current application does not meet the Medicines Act conditions for marketing authorization. Key issues include:
1. Developing an assay method for impurities below 0.1%
2. Providing additional evidence of double-blinding in long-term follow-up studies
3. Addressing remaining questions about data analysis
Nymox believes it has the necessary data for resubmission but cannot guarantee resolution of all issues. The company's MAA to the UK's MHRA is still in process. No significant safety concerns were reported for Nymozarfex in human clinical trials.
Summary not available.
Summary not available.